Our 2017 Good Pharma Scorecard Rankings are published!

We published our 2017 Good Pharma Scorecard Rankings on December 5th in BMJ open.  The Scorecard shows meaningful progress has been made on several key transparency metrics since the first Scorecard was released in 2015:

  • the proportion of new drugs with all phase 2 or 3 trials disclosed from their NDAs went up from 50% in the 2015 rankings to 67%, and
  • the public availability of results for trials conducted in patients for each drug, went up from a median of 87% to 96%, measured at 13 months post FDA approval.

Two companies tied for first place: J&J and Sanofi.  AbbVie, Celgene, Merck and AstraZeneca all scored at or above the industry median.